Yeah it does but the mkt cap is so undervalued I’m planning to just sit on it for proper valuation as levers get unlocked in future

$5 calls sounds nice but seriously it’s so close from current pps. If someone was buying $50 calls wake me up please. That’s the kind of potential this stock has purely based on fundamentals as they backfill the story imo $CAPR

$CAPR here’s all the funding capricor has got in the past when they were so much lesser of a co.
You think with all the focus on COVID and work they’re doing, it’s not possible for them to get funding lmao? https://projectreporter.nih.gov/reporter_searchresults.cfm

Skate to where the puck will be imo. This is the perfect time to swing this stock just above $4 line imo $CAPR

$CAPR nobody seems to have caught this yet?

Patent from June 2020: Method of preventing or treating radiation-induced dermatitis with extracellular vesicles

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=Capricor&OS=Capricor&RS=Capricor

Will come when mkt least expects it. Will gap $20-$30 the next open. Silly to not have solid position at all times here imo

Thx

Lmao. This turd will go back under a buck. She heavy imo

Best ceo golden ceo lol lol lol.

Miss that dude

Gap coming

When is RS

Bull gates lmao

Just imagine if a dude like bull gates puts money in Capricor. Not far fetched. Gould has hung out with him in the past

$CAPR Gould is already in touch with Gates imo. They had a meeting back in Nov so no reason why they’d not be talking now. Speculation here but there is history https://t.co/bmdBJHKfA1

— Rogerthat1 (@rogerthat191) May 26, 2020

It’s possible. Really is at some point. Don’t know how they PR some of this stuff and line up next steps but co is truly sitting on some ground breaking stuff. I paid attention when Linda said in hcw ppt - please pay attention news coming from Capricor and some of the research papers that will be published. She wasn’t kidding imo.

$CAPR Excellent results here on very low doses of mRNA ( 20 times smaller dose than expected to deliver to larger animals and Humans. Strong CD4+ and CD8+ TCell durable responses. This is what we needed to show to predict long term efficacy. As well TCell responses were seen for both S and N proteins. This next generation vaccine will replace the first generation which only targets S protein and generates mainly a humoral antibody response. N protein generates mainly a TCell response. We get the best of both worlds. Safety is also a Main factor for vaccine acceptance and it was met with flying colours. All IMO from my understanding. EXOSOMES based Vaccines and Drug Delivery Platform have now been officially validated. BO coming eventually. IMO

$CAPR
“Taken together, these results validate the use of exosomes for delivering functional mRNAs into target cells in vitro and in vivo, and more specifically, establish that LSNME/SW1 vaccine induced broad immunity to multiple SARS-CoV-2 proteins.” https://www.biorxiv.org/content/10.1101/2020.11.06.371419v1.full.pdf

??

Don’t get left behind imo. Go slap that ask on Monday

Exosome-Mediated mRNA Delivery For SARS-CoV-2 Vaccination
*Shang-Jui Tsai, *Chenxu Guo, ^Nadia A. Atai, and *Stephen J. Gould

https://www.biorxiv.org/content/10.1101/2020.11.06.371419v1.full.pdf

$CAPR posted yesterday. Next week big week imo. Closed the week at $4 line.

Exosome-Mediated mRNA Delivery For SARS-CoV-2 Vaccination
*Shang-Jui Tsai, *Chenxu Guo, ^Nadia A. Atai, and *Stephen J. Gould

https://www.biorxiv.org/content/10.1101/2020.11.06.371419v1.full.pdf

Lol. I bought my entire position after that talk. I liked that presentation

They listened to Linda HCW presentation in early sept. And then went to talk to her imo

$CAPR BlackRock Inc. reports 900.77% increase in ownership of CAPR

https://www.nature.com/articles/s41587-020-0725-7

$CAPR next week fireworks here imo. Exosomes news before conf, talk co up at the conf and then ER Thu AH

$CAPR globenewswire.com/news-rele...

https://www.globenewswire.com/news-release/2020/11/02/2118122/0/en/Sanofi-offers-to-acquire-Kiadis-a-clinical-stage-company-developing-cell-based-immunotherapy-products.html

$SNY Sanofi offers to acquire Kiadis for €308 million

Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK cells from a healthy donor.

KNK-ID-101 is a program evaluating the properties of K-NK cells and their suitability to fight SARS-CoV-2 and the option to develop K-NK cells as a post-exposure pre-emptive therapy for COVID-19 in high risk patients. Kiadis plans to initiate a phase 1/2a clinical trial evaluating use of K-NK cells to treat COVID-19 patients with government grant funding.

Can you link the article you read?

$CAPR also pay attention to this filing on exosomes ip https://www.sec.gov/Archives/edgar/data/1133869/000110465920098381/tm2029227d1_8k.htm

$CAPR if you’re long here or on the fence take some time and listen to the HCW ppt. Pay attention to what Linda says 7-10 min mark. As and when they PR some of this stuff out mkt will take notice in a big way.

https://wsw.com/webcast/hcw7/capr/1595926

$CAPR 7% of shares short here.

Share Statistics
Avg Vol (3 month) 3 1.52M
Avg Vol (10 day) 3 347.45k
Shares Outstanding 5 19.72M
Float 19.21M
% Held by Insiders 1 9.21%
% Held by Institutions 1 3.69%
Shares Short (Oct 15, 2020) 4 1.32M
Short Ratio (Oct 15, 2020) 4 1.29
Short % of Float (Oct 15, 2020) 4 6.88%
Short % of Shares Outstanding (Oct 15, 2020) 4 6.71%
Shares Short (prior month Sep 15, 2020) 4 1.46M

$CAPR Ceo presenting on Nov 12 on exosomes digital conf. No PR yet.

Development of Therapeutic Exosomes
• Exosomes as a vaccine for COVID-19
• CAP-1002 for the treatment of COVID-19

$CAPR Ceo presenting on Nov 12 on exosomes digital conf. No PR yet. pic.twitter.com/H3GbwKuEVI

— Rogerthat1 (@rogerthat191) October 31, 2020

https://www.epmmagazine.com/2nd-digital-exosome-therapeutics-development-summit-advancin/

Exosomebased-tx.com

Ceo presenting in early nov on exosomes

Very correct on that last piece you said

Yup. We will see a dip possibly under the $4 line

Not far fetched in your projections to be honest.

Thx Donald. So no private for me. Hit me on Twitter if you like rogerthat191@

Agree. Call this guy and ask that question imo.

AJ Bergmann | Chief Financial Officer
Capricor Therapeutics, Inc. | NASDAQ: CAPR
8840 Wilshire Boulevard – 2nd Floor, Beverly Hills, CA 90211
Office 310 358 3202 | Cell 703 624 7239 | Fax 310 358 3209
abergmann@capricor.com | www.capricor.com

If she goes to prison who will babysit her grandkids? Their teenage mom?

Spoke with the co this week. Dmd AA is very much on the table with fda. Active discussions currently. This pull down is just a fake out imo. $CAPR

Lmao. $CAPR

Lmao. Clueless